Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016', provides in depth analysis on Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted pipeline therapeutics. 

The report provides comprehensive information on the Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22)
- The report reviews Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Overview 8
Therapeutics Development 9
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Stage of Development 9
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Therapy Area 10
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Indication 11
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Companies 15
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Universities/Institutes 20
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Therapeutics Assessment 22
Assessment by Monotherapy/Combination Products 22
Assessment by Mechanism of Action 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Companies Involved in Therapeutics Development 28
Beta Pharma, Inc. 28
Eli Lilly and Company 29
G1 Therapeutics, Inc. 30
Jiangsu Hengrui Medicine Co., Ltd. 31
Novartis AG 32
Onconova Therapeutics, Inc. 33
Pfizer Inc. 34
Sihuan Pharmaceutical Holdings Group Ltd. 35
Teijin Pharma Limited 36
ViroStatics srl 37
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Drug Profiles 38
abemaciclib - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
BPI-1178 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
FLX-925 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
G-1T28 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
G-1T38 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
GZ-381 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
MMD-37K - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ON-123300 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
palbociclib - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ribociclib succinate - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
SHR-6390 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecules to Inhibit Cyclin D1, CDK6, EGFR and VEGF for Oncology - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Dormant Projects 74
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Discontinued Products 75
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Featured News & Press Releases 76
Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy 76
May 31, 2016: Lilly Announces Webcast To Discuss Abemaciclib Data 77
May 23, 2016: Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types 77
May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO 78
May 18, 2016: MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer 79
May 10, 2016: Health Canada approves new first-line treatment for women living with metastatic breast cancer 80
Apr 20, 2016: Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting 81
Apr 19, 2016: Pfizer Announces Positive Top-Line Results For Phase 3 PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib) 82
Apr 15, 2016: G1 Therapeutics to Present Preliminary clinical data on CDK4/6 Inhibitor G1T28 at the 2016 American Association for Cancer Research Annual Meeting 83
Apr 15, 2016: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor G1T38 at the 2016 American Association for Cancer Research Annual Meeting 84
Mar 14, 2016: New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows 84
Mar 07, 2016: New therapeutic target in myeloma discovered 86
Mar 02, 2016: Drug combination slows breast cancer spread 87
Feb 19, 2016: Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer 88
Dec 29, 2015: New breast cancer drug may be effective against other types of cancer 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables

Number of Products under Development for, H1 2016 9
Number of Products under Development by Therapy Area, H1 2016 10
Number of Products under Development by Indication, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Products under Development by Companies, H1 2016 (Contd..2) 18
Products under Development by Companies, H1 2016 (Contd..3) 19
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Products under Investigation by Universities/Institutes, H1 2016 21
Assessment by Monotherapy/Combination Products, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Pipeline by Beta Pharma, Inc., H1 2016 28
Pipeline by Eli Lilly and Company, H1 2016 29
Pipeline by G1 Therapeutics, Inc., H1 2016 30
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 31
Pipeline by Novartis AG, H1 2016 32
Pipeline by Onconova Therapeutics, Inc., H1 2016 33
Pipeline by Pfizer Inc., H1 2016 34
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 35
Pipeline by Teijin Pharma Limited, H1 2016 36
Pipeline by ViroStatics srl, H1 2016 37
Dormant Projects, H1 2016 74
Discontinued Products, H1 2016 75